Innovative
Monoclonal Antibodies
Against Small Molecules
& Transmembrane Proteins

Receptor tyrosine kinase therapeutic monoclonal antibodies

Receptor tyrosine kinase therapeutic monoclonal antibodies · 06. February 2022

The therapeutic challenges of receptor tyrosine kinases

SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise

Anti-CD25 therapeutic monoclonal antibody strategies

SYnabs unique anti-CD25 anti-IL2R therapeutic antibody has shown great promise in clinical trials. SYnAbs antagonist anti-IL2Ra/Tac depletes Tregs for GvHD and cancer treatments.

IL1RAP, a new biomarker of interest for cancer targeting

SYnAbs unique monoclonal antibodies to IL1RAP